Overview

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Status:
NOT_YET_RECRUITING

Trial end date:
2026-08-31

Target enrollment:

Participant gender:

Summary

This is a multicenter, single-arm,Phase II clinical trial to explore the efficacy and safety of Eribulin combined with Sintilimab in the first-line treatment of unresectable locally advanced or metastatic HER2-negative breast cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Treatments:

eribulin
sintilimab